Glycoprotein IIb/IIIa Inhibitors Versus Standard Therapy in Patients With Myocardial Infarction and No-reflow

• Status: Unknown status
• Trial end date: 2020-08-01
• Target enrollment: 0
• Participant gender: All

Summary

Aim of the study is to examine the effects of glycoprotein IIb/IIIa inhibitors on reperfusion success assessed by cardiac magnetic resonance imaging in patients with myocardial infarction and angiographic evidence of no-reflow.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Luebeck
• Treatments: Krestin; polysaccharide-K

Criteria

Inclusion Criteria:

• ST-elevation myocardial infarction and non-ST-elevation myocardial infarction <48 h after symptom onset

• Angiographic evidence of no-reflow (Thrombolysis in Myocardial Infarction-flow grade ≤2) after primary percutaneous coronary intervention

• Age ≥18 years

• Informed consent

Exclusion Criteria:

• ST-elevation myocardial infarction and non-ST-elevation myocardial infarction patients with Thrombolysis in Myocardial Infarction-flow 3 after primary percutaneous coronary intervention

• Age ≤18 years

• Known pregnancy, breast-feeding or intend to become pregnant during the study period

• Contraindication for treatment with platelet inhibitors

• Known allergy to glycoprotein IIb/IIIa inhibitors, aspirin, or heparin

• Active peptic gastric or duodenal ulcer

• History of major surgery (including intracranial or intraspinal) <4 weeks

• Active bleeding or bleeding diathesis

• Stroke <2 years (ischemic and hemorrhagic)

• Known coagulation defect or relevant thrombocytopenia

• Arteriovenous malformations or aneurysm

• Severe liver insufficiency

• Renal insufficiency requiring dialysis

• Uncontrolled hypertension

• Hypertensive retinopathy

• Vasculitis

• Fibrinolysis <12 hours

• Contraindication for cardiac magnetic resonance imaging at study entry

• Patients without informed consent

• Participation in another trial